<DOC>
	<DOCNO>NCT02589600</DOCNO>
	<brief_summary>The goal study perform first fracture reduction clinical trial potent antiresorptive agent ( intravenous zoledronic acid ) vulnerable long-term care population .</brief_summary>
	<brief_title>Zoledronic Acid Osteoporotic Fracture Prevention ( ZEST II )</brief_title>
	<detailed_description>Although close 85 % frail woman long-term care ( LTC ) facility osteoporosis risk osteoporotic fracture nearly 10 time community dwell elderly , treated study scarce . It postulate frail , LTC woman annual infusion zoledronic acid , antiresorptive therapy osteoporosis , : 1. effective demonstrate fracture reduction ; 2. safe ; 3. identify baseline characteristic concomitant bone structure change associate favorable fracture reduction bone density response therapy . To address hypothesis , 1000 female LTC resident age 65 older screen order enroll 514 eligible randomization 3 year , randomize , double-blind , calcium vitamin D control trial antiresorptive agent zoledronic acid . Use intravenous , yearly agent avoids concern oral bisphosphonate side effect , poor absorption burden staff . Participants reside long-term care setting associate Division Geriatric Medicine , University Pittsburgh include woman multiple comorbid condition , functional cognitive impairment , limited mobility .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Osteoporotic Fractures</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>woman age ≥65 year include use assistive device maximize generalizability : 1 . Reside longterm care ( LTC ) ; 2 . Have : osteoporosis axial bone density ( spine , hip forearm bone mineral density ( BMD ) Tscore ≤ 2.5 SD ) ; previous adult fragility fracture spine hip ; , would treat base FRAX National Osteoporosis Foundation ( NOF ) treatment threshold 10 year risk ≥ 20 % major osteoporotic fracture ≥ 3 % hip fracture use femoral neck BMD . Men osteoporosis less common men initial ZEST 1 study include woman . Institutionalized woman subacute illness survive discharge &lt; 3 year . Women currently bisphosphonate , denosumab , teriparatide therapy bisphosphonate great 1 year previous 2 year bisphosphonates long acting . Patients calculate creatinine clearance &lt; 35 ml/min contraindication bisphosphonates ( allergy , hypocalcemia ) .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bone loss</keyword>
	<keyword>Frail Geriatric Women</keyword>
	<keyword>Nursing Home Patients</keyword>
	<keyword>Long-term Care Patients</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteoporotic Fractures</keyword>
</DOC>